A phase 2B study of CX-1739 in patients with central sleep apnea
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2016
At a glance
- Drugs CX 1739 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 08 Sep 2016 According to a RespireRx Pharmaceuticals media release, final results are expected to be published in the fourth quarter of 2016.
- 08 Sep 2016 Status changed from recruiting to active, no longer recruiting, as reported in a RespireRx Pharmaceuticals media release.
- 29 Mar 2016 According to RespireRx media release, data expected in the third quarter of 2016.